Clarify the Role of Vivjoa for Recurrent Yeast Infections

New oral Rx Vivjoa (oteseconazole) will be the first med approved for managing recurrent vulvovaginal candidiasis.

But this azole is only for patients with 3 or more yeast infections per year who are postmenopausal or permanently infertile.

Vivjoa is teratogenic in animals...and can stay in the body for up to 2 YEARS. So for now, it shouldn’t be used in ANY patient of childbearing potential, even those on contraceptives.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote